6533b871fe1ef96bd12d1a67
RESEARCH PRODUCT
Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
Maria Corina SerbanManfredi RizzoDaniel PellaMichal VrablíkNathan D. WongAlessandro CollettiOlivier DescampsMichel LangloisPeter P. TothChristos PitsavosNiki KatsikiGani BajraktariOlena MitchenkoMarat V. EzhovArrigo F G CiceroKausik K. RayGyörgy ParaghDimitri P. MikhailidisŽEljko ReinerBernhard PaulweberDragan DjuricDragos VinereanuAmirhossein SahebkarGustavs LatkovskisZlatko FrasLaurence S. SperlingMaciej BanachDemosthenes B. Panagiotakossubject
PhytochemicalsMedicine (miscellaneous)030204 cardiovascular system & hematologyPharmacologyIntestinal absorption0302 clinical medicineRisk FactorsDrug Interactions030212 general & internal medicineRandomized Controlled Trials as TopicNutrition and DieteticsEvidence-Based MedicineOrvostudományok3. Good healthObservational Studies as TopicLiverCardiovascular DiseasesFatty Acids Unsaturatedlipids (amino acids peptides and proteins)nutraceuticalposition papermedicine.medical_specialtyStatinCombination therapymedicine.drug_classKlinikai orvostudományok03 medical and health sciencesMeta-Analysis as TopiclipidmedicineHumansIntensive care medicineLife StyleTriglyceridesDyslipidemiasbusiness.industryProbioticsdyslipidemiaCholesterol HDLEvidence-based medicineCholesterol LDLmedicine.diseaseResidual riskIntestinal AbsorptionrecommendationsDietary SupplementsPosition paperObservational Studies as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemiadescription
In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-01-01 |